共 50 条
- [1] Potent small molecule TEAD inhibitors targeting the Hippo pathway exhibit antiproliferation in vitro and anti-tumor effect in vivoCANCER RESEARCH, 2020, 80 (16)Amidon, BenSyed, SakeenaCavanaugh, JillFrosch, HyejinNatarajan, PrabithaEcsedy, JeffreyMcGovern, KarenCastro, Alfredo C.
- [2] The Glutaminase Inhibitor Compound 968 Exhibits Potent In vitro and In vivo Anti-tumor Effects in Endometrial CancerANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (02) : 210 - 221Guo, HuiLi, WanhuPan, GuoyouWang, CongLi, DapengLiu, NaifuSheng, XiuguiYuan, Lingqin
- [3] Discovery of novel and potent TEAD inhibitors, orally available small molecules with anti-tumor activity in hippo pathway-dysregulated cancersMOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)Moon, SunghoCho, Seon YeonKim, MinhyeBeak, SoojeongKim, JinhyukKim, YongchanPark, SungilKim, Jung-InKim, HanseongLee, In SangNo, Kyoung Tai
- [4] Discovery and characterization of a new potent orally available CdC7 inhibitor with anti-tumor activityEJC SUPPLEMENTS, 2008, 6 (12): : 116 - 116Montagnoli, A.Vanotti, E.Rainoldi, S.Marchesi, V.Ciavolella, A.Croci, V.Patton, V.Albanese, C.Santocanale, C.Moll, J.
- [5] In vitro and in vivo anti-tumor activity of ARQ 751, a potent and selective AKT inhibitorCANCER RESEARCH, 2016, 76Yu, YiSavage, Ronald E.Eathiraj, SudharshanHall, TerenceSchwartz, BrianAbbadessa, Giovanni
- [6] Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivoSCIENTIFIC REPORTS, 2024, 14 (01):Trakoonsenathong, RonnakritKunprom, WarittaAphivatanasiri, ChaiwatYueangchantuek, PadchareePimkeeree, PasladaSorin, SupannikaKhawkhiaw, KullanatChiu, Ching-FengOkada, SeijiWongkham, SopitSaengboonmee, Charupong
- [7] Novel small molecule inhibitors of p97 demonstrate anti-tumor effects in vitro and in vivoMOLECULAR BIOLOGY OF THE CELL, 2013, 24Anderson, D.Djakovic, S.Kissvonsoly, S.Le Moigne, R.Rice, J.Rolfe, M.Soriano, F.Valle, E.Wang, J.Wong, S.Wustrow, D.Yakes, M.Yao, B.Zhou, H-J.
- [8] AP24534: an orally active kinase inhibitor that targets multiple pro-angiogenic receptors and exhibits potent anti-tumor activity in vivoEJC SUPPLEMENTS, 2008, 6 (12): : 174 - 174Rivera, V. M.DiRenzo, R.Berk, L.Wardwell, S.Ning, Y.Narasimhan, N. I.Xu, Q.Shakespeare, W. C.Wang, F.Clackson, T.
- [9] L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma in vitro and in vivoFRONTIERS IN PHARMACOLOGY, 2019, 10Zhu, MingfeiWang, HongWang, ChenglinFang, YanfenZhu, TongZhao, WeiliDong, XiaochunZhang, Xiongwen
- [10] CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunityPLOS ONE, 2023, 18 (06):Sullivan, Kathleen M. C.Vilalta, MartaErtl, Linda S.Wang, YuDunlap, CarolynEbsworth, KarenZhao, Bin N.Li, ShijieZeng, YibinMiao, ZhenhuaFan, PingchenMali, VenkatLange, ChristopherMcMurtrie, DarrenYang, JuLui, RebeccaScamp, RyanChhina, VickyKumamoto, AliceYau, SimonDang, TonEasterday, AshtonLiu, ShirleyMiao, ShichangCharo, IsraelSchall, Thomas J.Zhang, Penglie